Answers are grounded in this paper and cite their sources.
Ovarian stimulation is a critical step in most assisted reproductive technology (ART) programs, as it allows to obtain a large cohort of oocytes in one menstrual cycle, the size of which directly correlates with the number of embryos obtained. Today, one of the highest priority areas in reproductive medicine is a differentiated approach to selecting the most appropriate protocol for ovarian stimulation, taking into account the patient’s age, ovarian reserve, the presence of concomitant genital and extragenital pathologies that determine the predicted ovarian response to stimulation, in order to obtain an adequate number of oocytes and embryos and reducing the risk of possible complications. The trend towards a decrease drugs burden and, accordingly, the cost of therapy is closely associated with an increase in patient satisfaction. Despite the fact that for many years the «long» protocol of ovarian stimulation with gonadotropin-releasing hormone (GnRH) agonists has been the «gold standard» for infertility treatment, in recent years the protocols with gonadotropin-releasing hormone antagonists (antGnRH) have been used in most cycles. This review is devoted to the peculiarities of the use of GnRH analogues, in particular ganirelix, in ART programs, the role of this drug both in stimulated cycles and in cycles with frozen embryo transfer.
No takes yet. Share an insight, caveat, or question.
Denisova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: